Mer­ck KGaA in talks to sell its biosim­i­lars R&D ops as shake­out looms

The biosim­i­lars busi­ness is just get­ting es­tab­lished, but the shake­out among a group of high-pow­ered ri­vals is al­ready tak­ing shape.

Mer­ck KGaA CEO Ste­fan Os­chmann told re­porters this morn­ing that the com­pa­ny is deep in talks to sell its biosim­i­lars group, ac­cord­ing to Reuters, dick­er­ing on a unit that has been tar­get­ing some fa­mil­iar block­busters like Hu­mi­ra (Ab­b­Vie), Rit­ux­an (Roche) and Neu­las­ta (Am­gen).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.